EM1709H "Targeted Therapy: What Does the Internist Really Need to Know?" (IM GR-092917)

The purpose of this presentation is to familiarize the audience with the typical toxicities and drug interactions associated with the commonly used molecularly targeted agents in oncology.

Download Protocol

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Recognize the common and serious side effects of the VEGF inhibitors
  • Recognize the common and serious side effects of the EGFR inhibitors
  • Understand the cardiac risk of HER-2 directed therapy
  • Understand the cardiovascular risks of the ABL1 TKI’s
  • Recognize potential autoimmune toxicities associated with the immune checkpoint inhibitors and basic management strategies for these toxicities
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
10/04/2017
Course expires: 
11/03/2017
Cost:
$0.00

Photo:Jonathan Dowell, M.D. Jonathan E. Dowell, M.D.
Professor of Internal Medicine
Division of Hematology / Oncology
Chief, Section of Hematology / Oncology Veterans Affairs North Texas Healthcare System

Available Credit

  • 1.00 AMA

Accreditation Period

Course opens: 
10/04/2017
Course expires: 
11/03/2017

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome